Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 743733 10.3389/fphar.2021.743733 Pharmacology Correction Corrigendum: Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium Yao et al. Corrigendum: Pranoprofen Effect on VEGF and COX-2 Expression Yao Bangtao 1 * Wang Fei 2 Zhao Xiaogui 1 Wang Bei 1 Yue Xiaoli 3 * Ding Yuhua 2 * Liu Gang 1 * 1 Department of Ophthalmology, Nanjing Lishui District People’s Hospital, Lishui Branch of Southeast University Affifiliated Zhongda Hospital, Nanjing, China 2 Department of Ophthalmology, Jiangsu Province Hospital, The First Affifiliated Hospital of Nanjing Medical University, Nanjing, China 3 Department of Pathology, Nanjing Lishui District People’s Hospital, Lishui Branch of Southeast University Affifiliated Zhongda Hospital, Nanjing, China

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

 *Correspondence: Bangtao Yao, yaobamtao_njmu@163.com; Gang Liu, lg1974329@126.com; Yuhua Ding, dingyuhua_njmu@163.com; Xiaoli Yue, chyuech2020@163.com

This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

 13 08 2021 2021 12 743733 19 07 2021 29 07 2021 Copyright © 2021 Yao, Wang, Zhao, Wang, Yue, Ding and Liu. 2021 Yao, Wang, Zhao, Wang, Yue, Ding and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Effect of a Topical Nonsteroidal Anti-Inflammatory Drug (0.1% Pranoprofen) on VEGF and COX-2 Expression in Primary Pterygium by Yao, B., Wang, F., Zha,o X., Wang, B., Yue, X., Ding, Y., and Liu, G. (2021). Front. Pharmacol. 12:709251. doi: 10.3389/fphar.2021.709251 0.1% pranoprofen vascular endothelial growth factor cyclo-oxygen-ase-2 pterygium nonsteroidal anti-inflammatory drug

In the original article, there was a mistake in Table 3 as published. Some numbers were wrongly reported in the COX-2, r, and p-value columns. “Additionally, there were multiple errors in the Results section due to incorrectly reported or missing values, which have now been corrected or added into the article.” The corrected Table 3 appears below.

Correlations between levels of VEGF and COX-2 expression in primary pterygium patients.

Group No — COX-2 a r p-value
1 38 VEGF a Negative (−) Weak positive (+) Moderate positive (++) Strong positive (+++) 0.473 0.003
Negative (−) 6 0 0 0
Weak positive (+) 1 2 4 0
Moderate positive (++) 1 12 12 0
Strong positive (+++) 0 0 0 0
2 37 VEGF a — — — — 0.550 <0.001
Negative (−) 0 0 0 0
Weak positive (+) 1 6 1 0
Moderate positive (++) 0 5 17 2
Strong positive (+++) 0 1 2 2
3 40 VEGF a — — — — 0.413 0.008
Negative (−) 0 0 0 0
Weak positive (+) 1 2 4 0
Moderate positive (++) 0 2 24 2
Strong positive (+++) 0 0 4 1

Detection of the expressing level of VEGF and COX-2 by immunohistochemistry.

A correction has been made to the Results section, sub-section VEGF:

“The VEGF expression levels in the pterygium are listed in Tables 1 and 2. In group 1, there were 6, 7, 19, and 6 samples with a TS of 0, 3, 4, and 5, respectively. Six (15.8%), 7 (18.4%), and 25 (65.8%) samples were classified as negative (-), weak positive (+), and moderate positive (++), respectively. No samples were classified as strong positive (+++). In group 2, there were 1, 7, 13, 11, and 4 samples with a TS of 2, 3, 4, 5, and 6, respectively. One sample had a TS of 7. Eight (21.6%), 24 (64.9%), and 5 (13.5%) samples were classified as weak positive (+), moderate positive (++), and strong positive (+++), respectively. No sample was classified as negative (-). In group 3, there were 1, 6, 9, 19, and 3 samples with a TS of 2, 3, 4, 5, and 6, respectively. Two samples had a TS of 7. Seven (17.5%), 28 (70.0%), and 5 (12.5%) samples were classified as weak positive (+), moderate positive (++), and strong positive (+++), respectively. No sample was classified as negative (-) (Figures 1B,E,H) (Tables 1, 2).”

A correction has been made to the Results section, sub-section COX-2:

“The COX-2 expression levels in pterygium studied are listed in Tables 1, 2. In group 1, there were 3, 5, 4, 10, 9, and 7 samples with a TS of 0, 1, 2, 3, 4, and 5, respectively. Eight (21.1%), 14 (36.8%), and 16 (42.1%) samples were classified as negative (-), weak positive (+), and moderate positive (++), respectively. No samples were classified as strong positive (+++). In group 2, there were 1, 5, 7, 8, 12, and 4 samples with a TS of 1, 2, 3, 4, 5, and 6, respectively. One (2.7%), 12 (32.4%), 20 (54.1%), and 4 (10.8%) samples were classified as negative (-), weak positive (+), moderate positive (++), and strong positive (+++). In group 3, there were 1, 3, 1, 23, 9, and 3 samples with a TS of 1, 2, 3, 4, 5, and 6, respectively. One (2.5%), 4 (10.0%), 32 (80.0%), and 3 (7.5%) samples were classified as negative (-), weak positive (+), moderate positive (++), and strong positive (+++), respectively (Figure 1) (Tables 1, 2).”

A correction has been made to the Results section, sub-section Correlations Between TS and VEGF and COX-2 Expression:

“There were significant correlations between the TS and expression of VEGF and COX-2 in pterygial vascular endothelial cells within groups 1, 2, and 3 (all P < 0.05, Spearman's coefficient of correlation), as shown in Figure 2 and Table 3, respectively.”

Lastly, a correction has been made to the Results section, sub-section Group Comparisons:

“There were no significant differences in age, sex, eye type, combined systemic diseases, duration of the disease, IOP, and BCVA among the three groups (all p > 0.05). The TS and expression levels of VEGF and COX-2 in pterygium tissues in group 1 were significantly lower than those in groups 2 and 3 (all p < 0.05). However, there were no significant differences in TS and expression levels of VEGF and COX-2 between groups 3 and 2 (all P > 0.05) (Tables 1, 2).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.